ReviewThe clinical respiratory journal2026
New-Onset Vitiligo During Dupilumab Treatment: A Clinical Observation and Literature Review.
Review in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionVitiligo is a rare adverse event associated with dupilumab. This study aims to describe a case of new-onset vitiligo following dupilumab treatment in a Chinese patient and to systematically review the literature to characterize its clinical features.
methodsA retrospective case analysis was conducted on a 70-year-old male patient who developed vitiligo as a result of dupilumab treatment. Comprehensive clinical, imaging, laboratory, and treatment data were meticulously documented. A systematic literature review revealed a total of 20 cases of dupilumab-induced vitiligo, which were categorized into two subgroups: improved (n = 13) and nonimproved (n = 7), based on treatment outcomes. The clinical characteristics of these subgroups were compared using appropriate statistical tests.
resultsThe patient developed depigmented patches accompanied by gray hair 4 months after the initiation of dupilumab, with no repigmentation observed despite ongoing treatment. Among the 20 pooled cases, the majority of patients received dupilumab for the treatment of atopic dermatitis (17/20, 85.00%). The onset of vitiligo typically occurred within 3 months of dupilumab initiation (11/18, 61.11%). Most patients presented with new-onset vitiligo (13/17, 76.47%), and more than half (13/20, 65.00%) exhibited clinical improvement in vitiligo symptoms. Subgroup analysis indicated that the use of topical corticosteroids (p = 0.017) was significantly associated with favorable outcomes.
conclusionDupilumab rarely induces new-onset vitiligo, even after drug discontinuation, potentially through the activation of the Th1/IFN-γ pathway following IL-4R blockade. The use of topical corticosteroids may be associated with more favorable outcomes in patients with dupilumab-induced vitiligo, whereas discontinuing dupilumab might not ensure repigmentation. Clinicians should closely monitor for depigmentation in patients treated with dupilumab, particularly in those with immune dysregulation, as early recognition and the application of topical corticosteroids may improve prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.